Test dosing of brentuximab for skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of mycosis fungoides or Sezary syndrome (or lymphomatoid papulosis).
- Your skin disease must be at a certain stage (for mycosis fungoides/Sezary, stage IB or higher) or your doctor must feel you need treatment for lymphomatoid papulosis.
- Your overall health activity level must be good (ECOG 0–2).
- You must not be on other cancer medicines/treatments for this condition while in the study, and any prior systemic cancer treatment must be stopped at least 2 weeks before starting.
- Your nerve health must be safe: neuropathy (nerve damage) must be less than grade 2.
- Your kidneys and liver must work well enough (severe kidney impairment and moderate/severe liver impairment are not allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This Phase 2 trial studies the combination of brentuximab vedotin and bendamustine in people whose follicular lymphoma has come back or did not respond. It aims to shrink the lymphoma and improve outcomes after at least one prior treatment.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.